SYRE: Spyre Therapeutics, Inc. Stock

by  •  • Comments Off on SYRE: Spyre Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,271.58
Enterprise Value ($M) 1,355.82
Book Value ($M) 327.39
Book Value / Share 5.58
Price / Book 3.88
NCAV ($M) 327.38
NCAV / Share 5.58
Price / NCAV 3.88

Profitability (mra)
Return on Invested Capital (ROIC) -0.66
Return on Assets (ROA) -0.63
Return on Equity (ROE) -1.17

Liquidity (mrq)
Quick Ratio 7.32
Current Ratio 7.32

Balance Sheet (mrq) ($M)
Current Assets 421.08
Assets 421.09
Liabilities 93.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Venrock Healthcare Capital Partners III, L.P. 5.30 -28.09
11-14 13G/A Avoro Capital Advisors LLC 1.70 -51.88
11-14 13G/A Commodore Capital Lp 3.90 2.79
11-14 13G/A Perceptive Advisors Llc 5.70 10.20
11-12 13G/A Fmr Llc 15.00 15.81
11-08 13G BlackRock, Inc. 5.20 0.00
10-23 13G Deutsch Peter E. 6.99
04-25 13D/A Fairmount Funds Management LLC 11.17 439.01
02-14 13G Rtw Investments, Lp 6.20
02-14 13G/A Logos Global Management LP 0.40
02-14 13G/A Rock Springs Capital Management LP 0.00
02-14 13G/A Baker Bros. Advisors Lp 0.00
02-14 13G/A EcoR1 Capital, LLC 2.50
02-14 13G/A Nantahala Capital Management, LLC 0.00
02-13 13G/A Affinity Asset Advisors, LLC 1.81
02-13 13G/A Suvretta Capital Management, Llc 1.00
02-13 13G/A BCLS II Equity Opportunities, LP 0.00
02-13 13G/A Polar Capital Holdings Plc 1.05
02-08 13G/A Integrated Core Strategies (us) Llc 0.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-11-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-11-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-11-18 10-K/A re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. 2)
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-01 10-K/A re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. 1)
2024-02-29 10-K re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-16 298,507 653,148 45.70
2025-01-15 103,969 434,070 23.95
2025-01-14 179,180 432,391 41.44
2025-01-13 143,724 674,645 21.30

(click for more detail)

Similar Companies
STTK – Shattuck Labs, Inc. SVRA – Savara Inc.
SWTX – SpringWorks Therapeutics, Inc. SYRS – Syros Pharmaceuticals, Inc.
TARS – Tarsus Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io